Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arobella Medical is a medical device company headquartered in Plymouth, Minnesota, that specializes in low-frequency ultrasound technology for advanced wound care and management. Founded in 2006 by Dr. Eliaz Babaev, the company developed the Qoustic Wound Therapy System (QWTS), an FDA-cleared and CE-marked platform that utilizes 35 kHz cavitational ultrasound for selective debridement. The system's proprietary Qoustic Qurette™ allows clinicians to precisely fragment and remove necrotic tissue, biofilm, and bacteria while preserving healthy granulation tissue and promoting blood flow. Arobella's technology is indicated for a wide range of conditions, including diabetic foot ulcers, pressure sores, and burns, and it holds a unique FDA registration for the treatment of osteomyelitis. The company provides a portable, cost-effective alternative to traditional sharp debridement, aiming to improve healing rates and patient comfort in various clinical settings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arobella Medical.